Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

NSE : SPARCBSE : 532872ISIN CODE : INE232I01014Industry : Business SupportHouse : Sun Pharma

BSE146.155.75 (+4.1 %)

PREV CLOSE ( ) 140.40

OPEN PRICE ( ) 138.60

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 31946

TODAY'S LOW / HIGH ( )138.00 147.40

52 WK LOW / HIGH ( )109.2 240.95

NSE145.965.46 (+3.89 %)

PREV CLOSE( ) 140.50

OPEN PRICE ( ) 140.00

BID PRICE (QTY) 145.96 (5)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 370339

TODAY'S LOW / HIGH( ) 138.00 147.65

52 WK LOW / HIGH ( )109.3 241

Select year

(Rs.in Million)

Particulars

Mar 2025

Mar 2024

Mar 2023

Profit Before Tax

-3427.81

-3868.32

-2225.84

Adjustment

205.23

-109.12

69.93

Changes In working Capital

-468.62

-273.34

1411.08

Cash Flow after changes in Working Capital

-3691.20

-4250.78

-744.83

Cash Flow from Operating Activities

-3602.93

-4291.88

-691.18

Cash Flow from Investing Activities

1576.60

3915.27

-5482.78

Cash Flow from Financing Activities

1992.56

424.05

6167.55

Net Cash Inflow / Outflow

-33.78

47.44

-6.41

Opening Cash & Cash Equivalents

53.30

5.84

12.24

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Cash & Cash Equivalent of Subsidiaries under liquidations

Translation adjustment on reserves / op cash balalces frgn subsidiaries

Effect of Foreign Exchange Fluctuations

0.12

0.02

Closing Cash & Cash Equivalent

19.64

53.30

5.84